Skip to content

Screening, diagnosis and pathogenesis of peripheral neuropathy

Screening, diagnosis and pathogenesis of peripheral neuropathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026629
Enrollment
Unknown
Registered
2019-10-16
Start date
2019-10-31
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral neuropathy

Interventions

Gold Standard:Neuroelectrophysiological examination
magnetic&#32
resonance,&#32
examination

Sponsors

The First Affiliated Hospital of university of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Peripheral neuropathy patients and healthy volunteers. Facial neuritis and carpal tunnel syndrome are diagnosed according to the results of neuroelectrophysiology. For including diabetic patients with or without DPN symptoms and signs, the diagnosis of diabetes was based on the revised American diabetes association standard, which includes fasting glucose levels greater than or equal to 126 mg/dl (>=6.1 mmol/L) and postprandial 2h glucose levels greater than or equal to 200 mg/dl (>=11.1 mmol/L).

Exclusion criteria

Exclusion criteria: Multiple neurologic histories due to other etiologies, such as hereditary, alcoholic, metabolic, inflammatory, and toxic factors; Skin damage or swelling can interfere with nerve conduction; And a previous known history of wrist, leg or ankle fractures or surgery.

Design outcomes

Primary

MeasureTime frame
Shear wave elastography;Neuropathy score;Urine alpha 1- microglobulin, Urine beta 2- microglobulin, Urinary transferrin;Percentage of neutrophils, RBC volume distribution width, ratio of platelet to lymphocyte, uric acid, bilirubin, HbA1c, 25-hydroxyvitamin D;Neuromagnetic resonance lesion volume, hyperintense lesion load;

Secondary

MeasureTime frame
Cross sectional Area, Nervous circumference;MiRNA-106a, MiRNA-181C;

Countries

China

Contacts

Public ContactYuanbo Wu

The First Affiliated Hospital of university of Science and Technology of China

wuyuanbo@mail.ustc.edu.cn+86 17721438279

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026